Satoshi Tateshima, MD, DMSc

Professor UCLA Interventional Neuroradiology, CNS Endovascular Surgery. Inventor, Marathon Runner, Pilot. A samurai with wings. Tweets my own, ≠medical advice

[Satoshi Tateshima, MD, DMSc @STateshimaMD]

Pediatric pial AVFs are a distinct disease, not an AVM. Direct AV shunt without a nidus. Straightfoward curative embo is possible. This case was cured in a single session, 20 min fluoro-time, <1 hr total procedure time. Understanding the pathology changes everything.

[Satoshi Tateshima, MD, DMSc @STateshimaMD]

Glomus tympanicum: a remarkable atlas of middle ear blood supply. Superior tympanic A. from MMA, inferior tympanic A. from APA, small pharyngotympanic A. from APA, stylomastoid A. from Post. auricular A. But no labyrinthine A. from AICA or no caroticotympanic A. from ICA.

[Satoshi Tateshima, MD, DMSc @STateshimaMD]

C1 AV fistula — complete occlusion. Often treated surgically due to pial risk, but not all cases require open surgery. Selected anatomy (single feeder, no critical pial branch) → curative endovascular treatment is possible.　Key, anatomy. PT's symptoms improving very next day.

[NeuroNews @NN_publishing]

Toro Neurovascular has announced that the @US_FDA has granted 510(k) clearance for the Toro 88 super-bore catheter, marking the commercial introduction of the company’s first proprietary #neurovascular access catheter platform
@STateshimaMD @KanekaNV_USA
https://t.co/JXV8uI16k1

[Satoshi Tateshima, MD, DMSc @STateshimaMD]

Engineering challenge for 0.088 catheter systems: flexibility vs support. Toro addresses this with “Micro-flex Technology,” offering an interesting engineering solution. First-in-US cases went very well.

https://t.co/Kg0BYEBpgE

[Satoshi Tateshima, MD, DMSc @STateshimaMD]

Honored to be invited by @DCNSNeuro & Stroke Program at Univ of Calgary. Delivered two Grand Rounds (A Structured Approach to Clinical Innovation / Stentplasty for ICAD). It was a privilege discussing with remarkable faculty & staffs. Thank you for the warm welcome.

[Satoshi Tateshima, MD, DMSc @STateshimaMD]

A delayed AICA/PICA dissection detected on Day 7 after a negative Day 0 study. In high-grade or non-perimesencephalic SAH, repeat DSA at 5–7 days is mandatory—posterior circulation dissections can declare themselves late and rebleed if missed.

[Satoshi Tateshima, MD, DMSc @STateshimaMD]

Proud to share our latest work: enhanced vitronectin adsorption & faster endothelial coverage in vitro & in vivo, supporting a non-biomimetic yet biologically effective surface strategy https://t.co/I4yX7IJeIL

[Satoshi Tateshima, MD, DMSc @STateshimaMD]

First-ever FD Y-stenting -- not previsouly reported even in vitro -- achieved using an electrospun TUBE stent (NV Medtech). TUBE stent provides 60% surface coverage (vs ~30-35% for current metal FD). Presented in BRAIN 2025 & ABCWIN2026 Val-d'Isere.

[Satoshi Tateshima, MD, DMSc @STateshimaMD]

Tough M1 occlusion from Trousseau's synd.
3 passes-3 different strategies: anterior-division combined technique → posterior-div combo → aspiration only. With cancer-related clots, I dont repeat the same maneuver. Each pass teaches us clot's behavior. Each pass needs a new plan.

[Satoshi Tateshima, MD, DMSc @STateshimaMD]

At BRAIN 2025 sharing tips for stentplasty of acute large vessel occlusion with embedded ICAD. Works great in a curved lesion. Long plasty (>5min) helps. The more struts the better. Undersized Comaneci / Tiger work better than oversized one in my hands at least.

[Satoshi Tateshima, MD, DMSc @STateshimaMD]

World's first disclosure of the TUBE polymer flow diverter at BRAIN 2025 @brainconferenc1 — 60% coverage, 027 deliverability, Y-stenting capable.

[Satoshi Tateshima, MD, DMSc @STateshimaMD]

Benefits of long duration stentplasty using TG dilator compared to conventional rescue treatment for acute LVO with underlying ICAD are "continuous perfusion" & "ease of use". I will discuss this in my upcoming talk @svinsociety 2025 Orlando.

[Satoshi Tateshima, MD, DMSc @STateshimaMD]

JSNET Osaka 2025 Presidential Dinner went above and beyond — personalized mini-figures waiting at each seat (@TudorGJovin / Naoki Kaneko @UCLAStrokeINR / @oozaidat / @RaulNogueiraMD / @STateshimaMD / @dliebesk / @dyavagal ).

[Satoshi Tateshima, MD, DMSc @STateshimaMD]

Onyx Frontier DES 3x8

[Satoshi Tateshima, MD, DMSc @STateshimaMD]

Intolerable pulsatile #tinnitus due to petrous ICA stenosis inducing turbulence. After angioplasty & stenting (balloon mounted stent), #pulsatiletinnitus is completely gone.

[Satoshi Tateshima, MD, DMSc @STateshimaMD]

Acute stroke due to LVO with underlying ICAD is more common than we think. We need 1) new device for it, 2) increasing awareness of it, 3) improve detaction, 4) more clinical data.

[Jens Fiehler @Fie0815]

Positive 12M results in bailout PTA/Stenting in 🇨🇳REBOOT RCT. https://t.co/buTxIggXWS PTA/Stenting improved 1-year mRS (gOR, 1.34). Fewer stroke recurrences (4% vs. 13%). @_AdnanSiddiqui @Acandisgmbh @STateshimaMD @Cure4Stroke

[Satoshi Tateshima, MD, DMSc @STateshimaMD]

@Fie0815 @_AdnanSiddiqui @Acandisgmbh @Cure4Stroke This is consistent with the clinical data on stentplasty (TG dilator) for LVO with underlying ICAD. The data will be disclosed at JSNET Osaka in a week by me & also at SVIN Orlando in 3 weeks by Dr. Sakai. Bailout angioplasty w/wo stenting helps for a certain chort!

[Satoshi Tateshima, MD, DMSc @STateshimaMD]

Non conventional cavernous sinus access for cavernous dural fistula. External jugular vein - transverse facial vein - supraorbital vein - superior orbital vein to cavernou sinus. Once microcath reached to the shunting point, quick liquid embolic injection blocked the fistula.

[Satoshi Tateshima, MD, DMSc @STateshimaMD]

A new embolic stroke prevention device for TAVR. Ease of use is the key. In vitro testing shows better embolic protection performance than existing device.

https://t.co/gPOUYSGfFe